Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: An economic evaluation

Respiratory Medicine

Volumn 97, Issue 1, 2003, Pages 20-26

  Jones, P W ^a   Wilson, K ^b   Sondhi, S ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disorder; Cost effectiveness analysis; Quality of life; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; PLACEBO; SALBUTAMOL; SALMETEROL XINAFOATE;

ADULT; AGED; AMBULATORY CARE; ANAMNESIS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; ECONOMIC EVALUATION; FEMALE; FORCED EXPIRATORY VOLUME; GENERAL PRACTICE; HEALTH CARE COST; HEALTH STATUS; HOSPITAL COST; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; METERED DOSE INHALER; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOCIOECONOMICS; SYMPTOMATOLOGY; TIME;

EID: 0037234780     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1053/rmed.2002.1425     Document Type: Article

References (16)

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S120.
2. Madison JM, Irwin RS. Chronic obstructive pulmonary disease. Lancet 1998; 352: 467-473.
3. Silverman EK, Speizer FE. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am 1996; 80: 501-522.
4. Pelletier-Fleury N, Lanoe JL, Fleury B, Fardeau M. The cost of treating COPD patients with long term oxygen therapy in a French population. Chest 1996; 100: 411-416.
5. Thom TJ. International comparisons in COPD mortality. Am Rev Respir Dis 1989; 140: S27-S34.
6. Donohue W, Plummer A. Magnitude and usage of home oxygen therapy in the United States. Chest 1995; 107: 301-302.
7. Turner-Warwick M, Hudson ME, Corrin B, et al. Clinical Atlas of Respiratory Diseases. London: Gower Medical Publishing, 1990.
8. Mahler DA, Donahue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957-965.
9. Jones PW, Bosh T. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289.
10. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-821.
11. Jones PW, Quirck FH, Baveystock CM. The St. George's respiratory questionnaire. Respir Med 1991; 85 (Suppl B): 25-31.
12. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A selfcomplete measure for chronic airflow limitation - the St George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
13. Desgagne A, Castilloux AM, Angers J-F, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. PharmacoEconomics 1998; 13: 487-497.
14. Rutten-Van Molken MP, Van Doorslaer EK, Jansen MC, et al. Cost and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 151: 975-982.
15. Price DB, Cargill K, Wolfe S, Darby H. Salmeterol xinaoate: an analysis of outcomes and cost-effectiveness using a primary care database. Resp Med 1998; 92: 1302-1304.
16. Lorenzo G, Morici G, Drago A, et al. Efficacy, tolerability and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. Clin Ther 1998; 20: 1130-1148.